Ozempic could be the next target of Medicare drug price negotiations – here’s why

CNBC August 31, 2023
Annika Kim Constantino

Key Points

– Ozempic, the blockbuster diabetes treatment from Novo Nordisk, could be next in line to face price negotiations between manufacturers and Medicare.

– The Biden administration released the first 10 drugs that will be subject to those talks, a process that aims to lower the prices of medications that Medicare Part D spends the most on by 2026.

– Several Wall Street analysts expect Ozempic to be a top choice in 2025 due to the amount of money Medicare Part D already spends on the weekly injection.

Ozempic, the blockbuster diabetes treatment from Novo Nordisk, could be next in line in the price negotiations between manufacturers and Medicare.

The Biden administration this week released the...

Today's Sponsors

Today's Sponsor